Analyzing R&D Budgets: TG Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc.

Biotech R&D: TG Therapeutics vs. Rhythm Pharmaceuticals

__timestampRhythm Pharmaceuticals, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014528000031354781
Thursday, January 1, 2015714800043445817
Friday, January 1, 20161959400066489820
Sunday, January 1, 20172289400096886134
Monday, January 1, 201850337000153793000
Tuesday, January 1, 2019109450000148369000
Wednesday, January 1, 202090450000151934000
Friday, January 1, 2021104128000198532000
Saturday, January 1, 2022108630000112128000
Sunday, January 1, 202313495100076192000
Loading chart...

Infusing magic into the data realm

The Evolution of R&D Investments in Biotech

In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, TG Therapeutics consistently outpaced Rhythm Pharmaceuticals, peaking in 2021 with a 98% increase from its 2014 levels. However, by 2023, TG Therapeutics' R&D expenses saw a notable decline of 62% from its 2021 peak, reflecting potential strategic shifts or financial constraints.

Conversely, Rhythm Pharmaceuticals exhibited a steady upward trend, culminating in a 155% increase in R&D spending by 2023 compared to 2014. This growth underscores Rhythm's expanding focus on innovation and development. These trends highlight the varying strategies and market responses of these two biotech firms, offering valuable insights into their future directions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025